Literature DB >> 15333595

Depot testosterone with etonogestrel implants result in induction of azoospermia in all men for long-term contraception.

B M Brady1, M Walton, N Hollow, A T Kicman, D T Baird, R A Anderson.   

Abstract

BACKGROUND: Combined testosterone and progestogen preparations are a promising approach to male hormonal contraception. We investigated the effect of s.c. etonogestrel with depot testosterone on spermatogenesis in normal men over a period of 48 weeks.
METHODS: Fifteen healthy men received three s.c. 68 mg etonogestrel implants. Testosterone pellets (400 mg) were administered at 12 weekly intervals.
RESULTS: Nine men completed 48 weeks of treatment. Four subjects chose to discontinue after 6 months, one man withdrew from the study early for personal reasons and one was withdrawn due to illness. Sperm concentrations of <1 x 10(6)/ml were achieved in all men by 16 weeks of treatment. All men became azoospermic, although the time to achieve this varied from 8 to 28 weeks. Azoospermia was maintained in eight of the nine men treated for 48 weeks, one subject showing partial recovery from 40 weeks. Testosterone levels remained in the physiological range throughout. Treatment did not result in weight gain, change in body composition or decline in high-density lipoprotein cholesterol concentrations.
CONCLUSIONS: The combination of three etonogestrel implants with depot testosterone results in rapid and consistent suppression of spermatogenesis. This can be maintained for up to 1 year and may therefore be a suitable approach for a long-acting male hormonal contraceptive.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15333595     DOI: 10.1093/humrep/deh491

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  6 in total

1.  Impact of add-back FSH on human and mouse prostate following gonadotropin ablation by GnRH antagonist treatment.

Authors:  Eleftherios E Deiktakis; Eleftheria Ieronymaki; Peter Zarén; Agnes Hagsund; Elin Wirestrand; Johan Malm; Christos Tsatsanis; Ilpo T Huhtaniemi; Aleksander Giwercman; Yvonne Lundberg Giwercman
Journal:  Endocr Connect       Date:  2022-06-21       Impact factor: 3.221

Review 2.  Advances in male contraception.

Authors:  Stephanie T Page; John K Amory; William J Bremner
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

3.  Determinants of the rate and extent of spermatogenic suppression during hormonal male contraception: an integrated analysis.

Authors:  Peter Y Liu; Ronald S Swerdloff; Bradley D Anawalt; Richard A Anderson; William J Bremner; Joerg Elliesen; Yi-Qun Gu; Wendy M Kersemaekers; Robert I McLachlan; M Cristina Meriggiola; Eberhard Nieschlag; Regine Sitruk-Ware; Kirsten Vogelsong; Xing-Hai Wang; Frederick C W Wu; Michael Zitzmann; David J Handelsman; Christina Wang
Journal:  J Clin Endocrinol Metab       Date:  2008-02-26       Impact factor: 5.958

Review 4.  Testosterone replacement therapy and cardiovascular risk.

Authors:  Thiago Gagliano-Jucá; Shehzad Basaria
Journal:  Nat Rev Cardiol       Date:  2019-09       Impact factor: 32.419

5.  A highly-sensitive anti-Müllerian hormone assay improves analysis of ovarian function following chemotherapy for early breast cancer.

Authors:  Joyce Chai; A Forbes Howie; David A Cameron; Richard A Anderson
Journal:  Eur J Cancer       Date:  2014-07-11       Impact factor: 9.162

Review 6.  Testosterone Is a Contraceptive and Should Not Be Used in Men Who Desire Fertility.

Authors:  Amir Shahreza Patel; Joon Yau Leong; Libert Ramos; Ranjith Ramasamy
Journal:  World J Mens Health       Date:  2018-10-10       Impact factor: 5.400

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.